Replimune Group, Inc.

Replimune Group Inc. is a biotechnology company specializing in the development of oncolytic immunotherapies to treat cancer. These therapies use genetically modified viruses to selectively target and kill tumor cells, while simultaneously stimulating an immune response against the cancer. The company’s innovative approach leverages the principles of virology and immunotherapy, aiming to offer novel solutions for complex cancer types, including melanoma and non-small cell lung cancer. Replimune's pipeline focuses on various clinical-stage product candidates, each designed to address diverse oncology indications, and has potential implications across different therapeutic areas within the healthcare and life sciences industry. Headquartered in Woburn, Massachusetts, Replimune plays a significant role in advancing the field of cancer treatment, contributing to the ongoing evolution of personalized medicine and targeted therapeutic strategies in combating one of the leading global health challenges. With its commitment to research and development, the company aims to make impactful progress in the fight against cancer by enhancing the body's natural immune response to eradicate malignancies.